Phase I trial of systemic intravenous infusion of interleukin-13-Pseudomonas exotoxin in patients with metastatic adrenocortical carcinoma

Cancer Medicine

Volumn 4, Issue 7, 2015, Pages 1060-1068

  Liu Chittenden, Yi ^a   Jain, Meenu ^a   Kumar, Parag ^b   Patel, Dhaval ^a   Aufforth, Rachel ^a   Neychev, Vladimir ^a   Sadowski, Samira ^a   Gara, Sudheer K ^a   Joshi, Bharat H ^c   Cottle Delisle, Candice ^a   Merkel, Roxanne ^a   Yang, Lily ^a   Miettinen, Markku ^a   Puri, Raj K ^c   Kebebew, Electron ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

IL 13 PE; Maximum tolerated dose; Metastatic adrenocortical carcinoma; Pharmacokinetics; Phase I; Systemic administration

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ANTINEOPLASTIC AGENT; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CREATININE; CYTOTOXIN; INTERLEUKIN 13 PSEUDOMONAS EXOTOXIN A; INTERLEUKIN 13 RECEPTOR ALPHA2; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG; BACTERIAL TOXIN; EXOTOXIN; HYBRID PROTEIN; INTERLEUKIN 13; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; TOXA PROTEIN, PSEUDOMONAS AERUGINOSA; VIRULENCE FACTOR;

ACUTE KIDNEY FAILURE; ADOLESCENT; ADRENAL CORTEX CARCINOMA; ADULT; AGED; ANEMIA; AREA UNDER THE CURVE; ARTICLE; CHILL; CLINICAL ARTICLE; COUGHING; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE ESCALATION; DRUG HALF LIFE; DRUG SAFETY; DYSPNEA; EPISTAXIS; FALLING; FATIGUE; FEMALE; HEADACHE; HEMATURIA; HUMAN; HYPERKALEMIA; HYPERTENSION; HYPOALBUMINEMIA; HYPOCALCEMIA; HYPOKALEMIA; HYPOMAGNESEMIA; HYPONATREMIA; IMMUNOGENICITY; KIDNEY FAILURE; MALE; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; METASTATIC ADRENOCORTICAL CARCINOMA; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; PAIN; PERICARDIAL EFFUSION; PERIPHERAL EDEMA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEINURIA; QT PROLONGATION; SKIN BRUISING; THROMBOCYTOPENIA; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VOLUME OF DISTRIBUTION; WEIGHT GAIN; ADRENAL CORTEX NEOPLASMS; ADRENOCORTICAL CARCINOMA; BLOOD; CLINICAL TRIAL; INTRAVENOUS DRUG ADMINISTRATION; METASTASIS; MIDDLE AGED; PATHOLOGY; RETREATMENT; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADP RIBOSE TRANSFERASES; ADRENAL CORTEX NEOPLASMS; ADRENOCORTICAL CARCINOMA; ADULT; AGED; ANTIBODIES, NEUTRALIZING; ANTINEOPLASTIC AGENTS; BACTERIAL TOXINS; EXOTOXINS; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; INTERLEUKIN-13; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM METASTASIS; RECOMBINANT FUSION PROTEINS; RETREATMENT; TREATMENT OUTCOME; VIRULENCE FACTORS; YOUNG ADULT;

EID: 84953409288     PISSN: None     EISSN: 20457634     Source Type: Journal    
DOI: 10.1002/cam4.449     Document Type: Article

References (26)

1. Bilimoria, K. Y., W. T. Shen, D. Elaraj, D. J. Bentrem, D. J. Winchester, E. Kebebew, et al. 2008. Adrenocortical carcinoma in the United States: treatment utilization and prognostic factors. Cancer 113:3130-3136.
2. Fassnacht, M., R. Libe, M. Kroiss, and B. Allolio. 2011. Adrenocortical carcinoma: a clinician's update. Nat. Rev. Endocrinol. 7:323-335.
3. Kebebew, E., E. Reiff, Q. Y. Duh, O. H. Clark, and A. McMillan. 2006. Extent of disease at presentation and outcome for adrenocortical carcinoma: have we made progress? World J. Surg. 30:872-878.
4. Kerkhofs, T. M., R. H. Verhoeven, J. M. Van der Zwan, J. Dieleman, M. N. Kerstens, T. P. Links, et al. 2013. Adrenocortical carcinoma: a population-based study on incidence and survival in the Netherlands since 1993. Eur. J. Cancer 49:2579-2586.
5. Fassnacht, M., and B. Allolio. 2009. Clinical management of adrenocortical carcinoma. Best Pract. Res. Clin. Endocrinol. Metab. 23:273-289.
6. Husain, S. R., N. I. Obiri, P. Gill, T. Zheng, I. Pastan, W. Debinski, et al. 1997. Receptor for interleukin 13 on AIDS-associated Kaposi's sarcoma cells serves as a new target for a potent Pseudomonas exotoxin-based chimeric toxin protein. Clin. Cancer Res. 3:151-156.
7. Kawakami, M., K. Kawakami, J. L. Kasperbauer, L. L., Hinkley, M. Tsukuda, S. E. Strome, et al. 2003. Interleukin-13 receptor alpha2 chain in human head and neck cancer serves as a unique diagnostic marker. Clin. Cancer Res. 9:6381-6388.
8. Kioi, M., M. Kawakami, T. Shimamura, S. R. Husain, and R. K. Puri. 2006. Interleukin-13 receptor alpha2 chain: a potential biomarker and molecular target for ovarian cancer therapy. Cancer 107:1407-1418.
9. Kioi, M., S. Seetharam, and R. K. Puri. 2008. Targeting IL-13Ralpha2-positive cancer with a novel recombinant immunotoxin composed of a single-chain antibody and mutated Pseudomonas exotoxin. Mol. Cancer Ther. 7:1579-1587.
10. Joshi, B. H., G. E. Plautz, and R. K. Puri. 2000. Interleukin-13 receptor alpha chain: a novel tumor-associated transmembrane protein in primary explants of human malignant gliomas. Cancer Res. 60:1168-1172.
11. Debinski, W., and D. M. Gibo. 2000. Molecular expression analysis of restrictive receptor for interleukin 13, a brain tumor-associated cancer/testis antigen. Mol. Med. 6:440-449.
12. Fichtner-Feigl, S., W. Strober, K. Kawakami, R. K. Puri, A. Kitani. 2006. IL-13 signaling through the IL-13alpha2 receptor is involved in induction of TGF-beta1 production and fibrosis. Nat. Med. 12:99-106.
13. Jain, M., L. Zhang, M. He, E. E. Patterson, N. Nilubol, A. T. Fojo, et al. 2012. Interleukin-13 receptor alpha2 is a novel therapeutic target for human adrenocortical carcinoma. Cancer 118:5698-5708.
14. Shimamura, T., T. Fujisawa, S. R. Husain, B. Joshi, and R. K. Puri. 2010. Interleukin 13 mediates signal transduction through interleukin 13 receptor alpha2 in pancreatic ductal adenocarcinoma: role of IL-13 Pseudomonas exotoxin in pancreatic cancer therapy. Clin. Cancer Res. 16:577-586.
15. Hou, L., J. Du, J. Wang, Y. Liu, W. Sun, Y. Zheng, et al. 2010. Expression of IL-13Ralpha2 in liver cancer cells and its effect on targeted therapy of liver cancer. J. Cancer Res. Clin. Oncol. 136:839-846.
16. Debinski, W., N. I. Obiri, I. Pastan, and R. K. Puri. 1995. A novel chimeric protein composed of interleukin 13 and Pseudomonas exotoxin is highly cytotoxic to human carcinoma cells expressing receptors for interleukin 13 and interleukin 4. J. Biol. Chem. 270:16775-16780.
17. Joshi, B. H. and R. K. Puri. 2005. Optimization of expression and purification of two biologically active chimeric fusion proteins that consist of human interleukin-13 and Pseudomonas exotoxin in Escherichia coli. Protein Expr. Purif. 39:189-198.
18. Puri, R. K., P. Leland, N. I. Obiri, S. R. Husain, R. J. Keitman, G. P. Haas et al. 1996. Targeting of interleukin-13 receptor on human renal cell carcinoma cells by a recombinant chimeric protein composed of interleukin-13 and a truncated form of Pseudomonas exotoxin A (PE38QQR). Blood 87:4333-4339.
19. Joshi, B. H., K. Kawakami, P. Leland, and R. K. Puri. 2002. Heterogeneity in interleukin-13 receptor expression and subunit structure in squamous cell carcinoma of head and neck: differential sensitivity to chimeric fusion proteins comprised of interleukin-13 and a mutated form of Pseudomonas exotoxin. Clin. Cancer Res. 8:1948-1956.
20. Kunwar, S., M. D. Prados, S. M. Chang, M. S. Berger, F. F. Lang, J. M. Piepmeier, et al. 2007. Direct intracerebral delivery of cintredekin besudotox (IL13-PE38QQR) in recurrent malignant glioma: a report by the Cintredekin Besudotox Intraparenchymal Study Group. J. Clin. Oncol. 25:837-844.
21. Kioi, M., S. R. Husain, D. Croteau, S. Kunwar, and R. K. Puri. 2006. Convection-enhanced delivery of interleukin-13 receptor-directed cytotoxin for malignant glioma therapy. Technol. Cancer Res. Treat. 5:239-250.
22. Vogelbaum, M. A., J. H. Sampson, S. Kunwar, et al. 2007. Convection-enhanced delivery of cintredekin besudotox (interleukin-13-PE38QQR) followed by radiation therapy with and without temozolomide in newly diagnosed malignant gliomas: phase 1 study of final safety results. Neurosurgery 61:1031-1037; discussion 1037-1038.
23. Kunwar, S., S. Chang, M. Westphal, M. Vogelbaum, J. Sampson, G. Barnett, et al. 2010. Phase III randomized trial of CED of IL13-PE38QQR vs Gliadel wafers for recurrent glioblastoma. Neuro Oncol. 12:871-881.
24. Kunwar, S., S. M. Chang, M. D. Prados, M. S. Berger, J. H. Sampson, and D. Croteau, et al. 2006. Safety of intraparenchymal convection-enhanced delivery of cintredekin besudotox in early-phase studies. Neurosurg. Focus 20:E15.
25. Ou, W., M. P. Marino, A. Suzuki, B. Joshi, S. R. Husain, A. Maisner, et al. 2012. Specific targeting of human interleukin (IL)-13 receptor alpha2-positive cells with lentiviral vectors displaying IL-13. Hum. Gene Ther. Methods 23:137-147.
26. Blake-Haskins, J. A., R. J. Lechleider, and R. J. Kreitman. 2011. Thrombotic microangiopathy with targeted cancer agents. Clin. Cancer Res. 17:5858-5866.